AIM ImmunoTech Inc. (NYSE:AIM) CEO Thomas K. Equels Acquires 61,729 Shares of Stock

AIM ImmunoTech Inc. (NYSE:AIM) CEO Thomas K. Equels purchased 61,729 shares of AIM ImmunoTech stock in a transaction that occurred on Monday, May 6th. The stock was acquired at an average price of $0.41 per share, for a total transaction of $25,308.89. Following the transaction, the chief executive officer now directly owns 778,184 shares of the company’s stock, valued at approximately $319,055.44. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

AIM ImmunoTech Trading Up 1.2 %

Shares of NYSE AIM opened at $0.43 on Wednesday. The stock has a market capitalization of $21.57 million, a price-to-earnings ratio of -0.71 and a beta of -0.11. AIM ImmunoTech Inc. has a 12-month low of $0.32 and a 12-month high of $0.75. The firm’s 50-day moving average price is $0.43 and its 200-day moving average price is $0.44.

AIM ImmunoTech (NYSE:AIM) last posted its quarterly earnings data on Friday, March 29th. The company reported ($0.26) earnings per share (EPS) for the quarter. The company had revenue of $0.07 million during the quarter. AIM ImmunoTech had a negative net margin of 14,337.62% and a negative return on equity of 121.69%.

About AIM ImmunoTech

AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).